The “STING Pathway Targeting Therapeutics and Technologies, 2020-2030” report features an extensive study of the current market landscape and future potential of these therapeutics and affiliated technologies, over the next d
The “STING Pathway Targeting Therapeutics and Technologies, 2020-2030” report features an extensive study of the current market landscape and future potential of these therapeutics and affiliated technologies, over the next d
STING, having generated significant interest within the medical research community, is currently considered one of the fastest growing areas of cancer immunotherapy.

To order thisdetailed 310+ page report, please visit this link



Key Inclusions


§ A detailed assessment of the current market landscape oftherapeutics targeting STING pathway, based on several parameters, such as typeof STING modulator (agonist or antagonist), type of molecule (small molecules,cyclic dinucleotides, non-nucleotides, biologics and others), phase ofdevelopment (discovery, preclinical and clinical), target therapeutic area(s),type of therapy (monotherapy and combination therapy), route of administration(intratumoral, intravenous and others), and line of treatment (last line,second line or greater and first line or greater). The chapter also features ananalysis of the developer landscape (including information on year ofestablishment, company size, geography and most active players). Further thechapter includes an analysis on the clinical trials focused on STING, alongwith information on parameters, such as recruitment status, study design andclinical endpoints.

§ A detailed chapter highlighting various technologyplatforms that are being actively used for the development of STING modulatorsand analysis based on several parameters, such as type of modulator (agonist orantagonist), type of molecule (small molecules, cyclic dinucleotides,non-nucleotides, live biotherapeutics, nanoparticles and synthetic peptides),and analysis based on technology developer landscape (including information onyear of establishment, company size and geography).

§ Elaborate profiles of key players that are engaged in thedevelopment of therapeutics targeting STING pathway (shortlisted on the basisof phase of development of pipeline products), featuring a brief overview ofthe company, its financial information (if available), detailed descriptions oftheir respective lead drug candidates, recent developments and an informedfuture outlook. Additionally, each drug profile features information on thetype of drug, route of administration, target indications and current status ofdevelopment.

§ Tabulated profiles of industry players (shortlisted on thebasis of the antagonist in pipeline products), featuring details on theinnovator company (such as year of establishment, location of headquarters,number of employees, key members of the executive team and recentdevelopments), along with descriptions of their respective drug candidates.

§ A study on various grants that have been awarded toresearch institutes engaged in projects related to STING pathway, during theperiod 2015 - Q1 2020, based on multiple parameters, such as number of grantsawarded, amount awarded, funding institute, support period, funding mechanism,type of grant application, grant activity code, most popular NIH department,type of recipient organization, regional distribution, most popular recipientorganization(s), prominent project leader(s) and study section. It alsoincludes an analysis of on grant attractiveness.

§ An analysis of big pharma players engaged in thedevelopment of therapeutics targeting STING pathway, based on severalparameters, such as portfolio diversity, type of molecule, phase ofdevelopment, therapeutic area(s), type of therapy and route of administration.In addition, the chapter features a benchmarking analysis of the aforementionedplayers.

§ An analysis of the start-ups / small players (establishedin the last ten years, less than 50 employees) engaged in the development oftherapeutics targeting STING pathway, based on several relevant parameters,such as portfolio diversity, type of molecule, phase of development,therapeutic area, funding received, number of investors, type of funding,partnership activity, number of patents filed, grants received, and start-uphealth indexing.

§ A detailed publication analysis of more than 300peer-reviewed, scientific articles that have been published during the period2019 - Q1 2020, highlighting the research focus within the industry. It alsohighlights the key trends observed across publications, including informationon type of publication, year of publication, study objective, popular keywords,type of STING modulator, target pathway, therapeutic area, type of publisher,leading players (in terms of number of publications), region, first authororganization and key journals (in terms of number of articles published in thisdomain).

§ An analysis of the partnerships that have been establishedin the domain, over the period 2015 - Q1 2020, covering research agreements,product / technology licensing agreements, mergers / acquisitions,  R&D and commercialization agreements, IPlicensing agreements, clinical trial agreements, product developmentagreements, and other relevant deals. The chapter highlights analysis based onyear of partnerships, type of partnership model, type of STING modulator,therapeutic area, technology platform, most active player(s) (in terms ofnumber of partnerships inked), and region.

§ An analysis of the investments made at various stages ofdevelopment, such as seed financing, venture capital financing, debt financing,grants / awards, capital raised from IPOs and subsequent offerings, bycompanies engaged in this field. The chapter highlights analysis based on thenumber of funding instances, amount invested, type of funding, type of STINGmodulator, therapeutic area, technology platform, most active player(s) (interms of number of funding instances), most active investor(s) (in terms ofnumber of funding instances) and geographical region.


The report also features thelikely distribution of the current and forecasted opportunity across important marketsegments, mentioned below:

§ Types of Payment

§ Upfront Payments

§ Milestone Payments


§ Type of STINGModulator

§ Agonist

§ Antagonist


§ Key TherapeuticArea(s)

§ Oncological Disorders

§ InflammatoryDisorders

§ Infectious Diseases

§ Others


§ Route of Administration

§ Intratumoral

§ Intravenous

§ Oral

§ Subcutaneous

§ Others


§ Type of Molecule

§ Non-nucleotide

§ Cyclic Dinucleotide

§ Live Biotherapeutics

§ Oncolytic Peptides

§ Synthetic Peptides

§ Others


§ Key GeographicalRegions

§ North America

§ Europe

§ Asia-Pacific 


To request samplepages, please visit this link


Key Questions Answered

§  Who arethe leading developers of STING pathway targeting therapeutics and affiliatedtechnologies?

§  What arethe most popular STING pathway related technology platforms in the market?

§  What arethe key therapeutic areas for which STING pathway targeting therapeutics arebeing / have been developed?

§  What kindof partnership models are commonly adopted by stakeholders engaged in thisindustry?

§  What isthe trend of capital investment for STING pathway targeting therapeutics andtechnologies?

§ How is the current and future opportunity likely to be distributedacross key market segments in this domain?


You may also be interested in the followingtitles:

1.       Nuclear Medicine and RadiopharmaceuticalsManufacturing Market, 2020-2030

2.     Global PsychedelicTherapeutics Market by Type of Psychedelic Substance (Ketamine, Psilocybin,MDMA and Others), by Origin (Natural and Synthetic), by Type of Therapy(Monotherapy, Combination and Others), by Route of Administration (Oral,Intravenous, Intranasal and Others) and by Key Geographies (North America,Europe and Asia- Pacific and rest of the world): Industry Trends and GlobalForecasts, 2020-2030

3.      Endocannabinoid SystemTargeted Therapeutics Market, 2020-2030


Contact Us

Gaurav Chaudhary

+1 (415) 800 3415